CN1557311A - Fibrauretine capsule tablet and its preparation method - Google Patents
Fibrauretine capsule tablet and its preparation method Download PDFInfo
- Publication number
- CN1557311A CN1557311A CNA2004100017668A CN200410001766A CN1557311A CN 1557311 A CN1557311 A CN 1557311A CN A2004100017668 A CNA2004100017668 A CN A2004100017668A CN 200410001766 A CN200410001766 A CN 200410001766A CN 1557311 A CN1557311 A CN 1557311A
- Authority
- CN
- China
- Prior art keywords
- coating
- label
- fibrauretin
- tablet
- coated tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The fibrauretine coating tablet is prepared with fibrauretine as active component, and through mixing with at least one kind of supplementary material including stuffing, wetting agent, adhesive, disintegrating agent and lubricant; pelletizing, drying and tabletting core; and covering the core with coating film to form the coating tablet. The coating tablet may be sugar-coated tablet, film coated tablet or enteric coated tablet. After being orally taken, the fibrauretine coating tablet is leached and absorbed in gastrointestinal tract and has no bitter tasted and no irritation to stomach. Each tablet contains fibrauretine in 10-1000 mg.
Description
Technical field
The present invention relates to a kind of process innovation of fibrauretin preparation, particularly a kind of fibrauretin coated tablet and preparation method thereof.
Background technology
Fibrauretin (Fibrauretnum) is the alkaloid that extracts from the stem of menispermaceae plant Caulis Fibraureae (Fibraurea recisn Pierre), molecular formula C
22H
22O
4HCl3H
2O is yellow acicular crystal, and 198～201 ℃ of fusing points, flavor are extremely bitter, odorless.Easily molten in hot water, molten in the water part omitted, slightly soluble in ethanol and chloroform, almost insoluble in ether.This product has the effect of stronger mould fungus inhibition, staphylococcus, gonococcus, mycoplasma chlamydia, acid-resisting analysis of bacillus, be used for diseases such as gynecological inflammation, bacillary dysentery, diarrhoea, enteritis, respiratory tract and urinary tract infection, surgical infection, eye conjunctivitis clinically, receive good effect, found no any toxic and side effects.
Fibrauretin has recorded in version " Chinese pharmacopoeia in 1977, with the fibrauretin is preparation fibrauretin sheet (plain sheet), fibrauretin bolt and the fibrauretin injection that effective ingredient is made, these preparations are ratified to produce in accordance with the law, and put sale on market, its quality standard records respectively in version " Chinese pharmacopoeia and local drug standard in 1977.For many years, be used for from clinical the making of fibrauretin preparation, because use inconvenience of fibrauretin suppository and indication are few, the clinical practice amount seldom; The existence of fibrauretin injection is carried and the administration inconvenience; Fibrauretin sheet (plain sheet) lacks the doctor from property because of flavor is extremely bitter, and many patients are difficult to swallow and abandoning cure, and the clinical expansion that these situations have influenced fibrauretin sheet, fibrauretin bolt and fibrauretin injection uses.
Summary of the invention
The purpose of this invention is to provide a kind of is the oral coated tablet of active component with the principal agent fibrauretin, by with tablet coating, oral cavity, esophagus, stomach directly contact with fibrauretin when having avoided the patient to take medicine, so both kept the advantage that tablet carries convenient drug administration, overcome bitter in the mouth and medicine irritating weak point again to stomach, be convenient to the patient and use, improve the effect of patient doctor from property.
Pharmaceutical preparation provided by the invention belongs to Western medicine 5 kind new medicines according to the regulation of " provisions for new drugs approval " that Ministry of Health of the People's Republic of China formulates.A kind of is the fibrauretin coated tablet of active component with the principal agent fibrauretin, and it is made up of label and coating membrane, it is characterized in that containing fibrauretin 10mg～1000mg by active component in the every label.Contain 50mg or 100mg or 200mg by every of active component in the label of the coated tablet of clinical recommendation.
Label of the present invention is mixed and made into by at least a adjuvant in principal agent fibrauretin and filler, wetting agent, binding agent, disintegrating agent, the lubricant; The weight proportion scope of principal agent and adjuvant is 1: 0.05----1: 500.
One of adjuvant of the present invention filler can adopt a kind of in starch, pregelatinized Starch, dextrin, Icing Sugar, lactose, microcrystalline Cellulose, calcium sulfate, calcium carbonate, the light magnesium oxide at least, and common dose be account for sheet heavy 30%～70%; The wetting agent of one of adjuvant can adopt distilled water or ethanol (30%～70%); The binding agent of one of adjuvant can adopt at least hypromellose (1%～10%), polyvidone (1%～20%), corn starch liquid (3%～30%), dextrin (3%～30%), syrup (10%～70%) (g/g), a kind of in gelatine size (10%～20%), mucialga of arabic gummy (10%～25%), cellulose and derivant (1%～10%) thereof, the Polyethylene Glycol; The disintegrating agent of one of adjuvant can adopt a kind of in crosslinked carboxycellulose sodium, polyvinylpolypyrrolidone, dry starch, carboxymethyl starch sodium, hydroxypropyl starch, low-substituted hydroxypropyl cellulose, sodium laurylsulfate, stearyl alcohol sodium sulfonate, bromination hexadecane trimethylamine, aluminium-magnesium silicate, kaolin, extra large bath acid, the leguminous plant glue at least, and common dose be account for sheet heavy 0.5%～20%; The lubricant of one of adjuvant can adopt a kind of in stearic acid, calcium stearate, magnesium stearate, zinc stearate, Stepanol MG, sodium lauryl sulphate, micropowder silica gel, Pulvis Talci, liquid paraffin, the sodium benzoate at least, and common dose be account for sheet heavy 0.1%～5%.
Slow releasing tablet and controlled release tablet that label of the present invention is made by principal agent fibrauretin and slow-release material, controlled-release material, wherein slow-release material, controlled-release material are made up of following, and it can adopt a kind of as thickening agent in gelatin, PVP, CMC, PVA, the dextran at least; At least can adopt MC, CMC-Na, HPMC, PVC, alginate, take off a kind of in ethyl acyl chitin, ethyl cellulose, polymethacrylates, the polyethylene as framework material; At least can adopt a kind of in Animal fat, Cera Flava, Brazil wax, hydrogenated vegetable oil, cellulose acetate phthalate ester, acrylic resin, hypromellose phthalate ester, the Hydroxypropyl Methyl Cellulose Phthalate as blocker.
The outer coating membrane that coats of label of the present invention is the enteric coating film, and it selects at least a among CAP, Lac, acrylic resin, the HPMCP for use.
The outer coating membrane that coats of label of the present invention is the sugar-coat film, and it comprises selects at least a as isolated material in 10%～15% rubber cement, 30%～35% mucialga of arabic gummy, 15%～20% Lac alcoholic solution, 10% zein alcoholic solution, the 10% cellulose acetate phthalate ester ethanol acetone soln for use; Select for use 65% (g/g) or 84% (g/ml) syrup as the sugarcoating layer material simultaneously; Selecting for use Pulvis Talci, Pulvis Talci to add 10%～20% calcium carbonate, Pulvis Talci adds 10%～20% magnesium carbonate, Pulvis Talci and adds at least a as the sub-coat material in 10%～20% starch; Select at least a in river wax, Cera Flava, the Brazil wax for use as the polishing agent.
The outer coating membrane that coats of label of the present invention is the film-coat film, and this film-coat film comprises selects at least a as the film-coat material in hypromellose, hydroxypropyl cellulose, ethyl cellulose, Polyethylene Glycol, polyvidone, esters of acrylic acid, zein, hydroxyethyl-cellulose, sodium carboxymethyl cellulose, the methylcellulose for use; Select at least a for plasticizer in propylene glycol, glycerol, FEG, triacetin, silicone oil, span, acetylation monoglyceride, the phthalic acid ester simultaneously for use; Select at least a in water, ethanol, isopropyl alcohol, the acetone for use as solvent.
A kind of preparation method of fibrauretin coated tablet, it is to produce label by wet granule compression tablet method or compressing dry granulation or direct compression process again after earlier principal agent and adjuvant being mixed, wherein (1) wet granule compression tablet method is, get fibrauretin and pharmaceutic adjuvant by weight ratio, add an amount of wetting agent or binding agent, stir and make soft material, granulate, dry back granulate adds the lubricant mixing, and tabletting makes; (2) compressing dry granulation is, gets fibrauretin and pharmaceutic adjuvant mixing by weight, and control moisture (about 4%) is pressed into bulk or big lamellar, is broken into granule, tabletting; (3) direct compression process is, gets after fibrauretin and the suitable auxiliary materials and mixing without granulation direct compression by weight; Last coating is made coated tablet, and described art for coating has the art for coating of (1), coated tablet: get qualified label, wrap 3～5 layers of sealing coat (40～50 ℃ of dryings) earlier with rubber cement, wrap sub-coat and sugarcoating layer again, must be dry layer by layer, polishing promptly gets coated tablet after quality inspection is qualified.(2) art for coating of Film coated tablets has, the pan coating method: get qualified label, coating material is sprayed on the label that is rolling equably, repeatable operation until forming film-coat, promptly gets Film coated tablets; Or air suspension coating: qualified label is placed the coating chamber, and thermal air current directly feeds the coating chamber, plain sheet is blown afloat make into suspended state, and coating solution is sprayed on the label continuously, promptly gets Film coated tablets after the drying; (3) art for coating of enteric coatel tablets has, the pan coating method: wrap sub-coat, enteric material and sugarcoating layer respectively promptly; Or it is similar with the coating of Film coated tablets.
A kind of preparation method of fibrauretin coated tablet, it is to produce fibrauretine sustained-release label, controlled release label earlier, its method is (1) with gelatin or vinyl acetate or Lac is that binding agent is made tabletting behind the granule; (2) microcapsule compressed tablet method: for the capsule material carries out microencapsulation, make microcapsule with the blocker, repress is made sheet; (3) medicine is made piller, and then tablet forming; With the coated coated tablet of making of the label of making, described art for coating has the art for coating of (1), coated tablet: get qualified label, wrap 3～5 layers of sealing coat (40～50 ℃ of dryings) earlier with rubber cement, wrap sub-coat and sugarcoating layer again, must be dry layer by layer, polishing promptly gets coated tablet after quality inspection is qualified.(2) art for coating of Film coated tablets has, the pan coating method: get qualified label, coating material is sprayed on the label that is rolling equably, repeatable operation until forming film-coat, promptly gets Film coated tablets; Or air suspension coating: qualified label is placed the coating chamber, and thermal air current directly feeds the coating chamber, plain sheet is blown afloat make into suspended state, and coating solution is sprayed on the label continuously, promptly gets Film coated tablets after the drying; (3) art for coating of enteric coatel tablets has, the pan coating method: wrap sub-coat, enteric material and sugarcoating layer respectively promptly; Or it is similar with the coating of Film coated tablets.
Fibrauretin coated tablet of the present invention is stable, injection and suppository medication inconvenience have been overcome, coated tablet neither influences the absorption of fibrauretin in intestinal, avoided the oral bitter in the mouth of patient to be difficult for accepting again, reduce the untoward reaction of medicine to stomach, while has also increased a kind of easy to use to the patient, clinical application is cured from the better preparation of property.
The specific embodiment
Below will the present invention will be described in detail by embodiment, comprise preparation method and in detail component etc. provide by the following example, but protection scope of the present invention is not limited to this.
Embodiment 1, choose following main materials and auxiliary materials composition by weight ratio: 50% fibrauretin, 45% starch, 4% carboxymethyl starch sodium, an amount of 5% hypromellose solution, 1% magnesium stearate, be made into fibrauretin coated tablet label of the present invention by the wet granule compression tablet method, promptly get fibrauretin and pharmaceutic adjuvant, add an amount of wetting agent or binding agent, stir and make soft material by above-mentioned weight proportion, granulate, dry back granulate adds the lubricant mixing, and tabletting makes; Above-mentioned label through making coating membrane outside label after, coating method of the present invention is become fibrauretin coated tablet of the present invention.
Embodiment 2, choose following main materials and auxiliary materials composition by weight ratio, 25% fibrauretin, 70% starch, 4% carboxymethyl starch sodium, an amount of 5% hypromellose solution, 1% magnesium stearate are made into fibrauretin coated tablet label of the present invention by the wet granule compression tablet method, promptly get fibrauretin and pharmaceutic adjuvant by above-mentioned weight proportion, add an amount of wetting agent or binding agent, stir and make soft material, granulate dry back granulate, add the lubricant mixing, tabletting makes; Above-mentioned label through making coating membrane outside label after, coating method of the present invention is become fibrauretin coated tablet of the present invention.
Embodiment 3, choose following main materials and auxiliary materials composition by weight ratio: 75% fibrauretin, 20% microcrystalline Cellulose, 4% carboxymethyl starch sodium, an amount of 5% hypromellose solution, 1% magnesium stearate, be made into fibrauretin coated tablet label of the present invention by the wet granule compression tablet method, promptly get fibrauretin and pharmaceutic adjuvant, add an amount of wetting agent or binding agent, stir and make soft material by above-mentioned weight proportion, granulate, dry back granulate adds the lubricant mixing, and tabletting makes; Above-mentioned label through making coating membrane outside label after, coating method of the present invention is become fibrauretin coated tablet of the present invention.
Embodiment 4, choose following main materials and auxiliary materials composition by weight ratio: 50% fibrauretin, 40% microcrystalline Cellulose, 5% carboxymethyl starch sodium, 3% polyvinylpyrrolidone K25 (dry powder), 2% magnesium stearate, be made into fibrauretin coated tablet label of the present invention by compressing dry granulation, promptly choose fibrauretin and pharmaceutic adjuvant mixing by above-mentioned weight proportion, control moisture (about 4%), be pressed into bulk or big lamellar, be broken into granule, tabletting forms; Above-mentioned label through making coating membrane outside label after, coating method of the present invention is become fibrauretin coated tablet of the present invention.
Embodiment 5, choose following main materials and auxiliary materials composition by weight ratio: 50% fibrauretin, 10% microcrystalline Cellulose, 4% cross-linked carboxymethyl cellulose, 17% sorbitol, 17% calcium hydrogen phosphate, 1% magnesium stearate, be made into fibrauretin coated tablet label of the present invention by direct compression process, promptly choose after fibrauretin and the suitable auxiliary materials and mixing without granulation direct compression by above-mentioned weight proportion; Last coating is made coated tablet.
Embodiment 6, choose the following raw materials according composition by weight ratio, make fibrauretine sustained-release label of the present invention by slow release label preparation method: it is that binding agent is made tabletting behind the granule with gelatin or vinyl acetate or Lac that 20% fibrauretin, 30% starch, 16% polyacrylic resin II, 16% hypromellose, 18% polyvidone, an amount of magnesium stearate, 6% an amount of starch slurry, its method of producing label have (1); (2) microcapsule compressed tablet method: for the capsule material carries out microencapsulation, make microcapsule with the blocker, repress is made sheet; (3) medicine is made piller, and then tablet forming; Above-mentioned label through making coating membrane outside label after, coating method of the present invention is become fibrauretin coated tablet of the present invention.
Embodiment 7, choose the coating material prescription of following weight or volume, make fibrauretin film-coat of the present invention (in every tablet recipe amount): 0.02mg Opadry (enteric), 0.016mg Pulvis Talci, 0.54ml 95% ethanol, 0.016mg Oleum Ricini, described art for coating has: the art for coating of Film coated tablets, promptly get qualified label, coating material is sprayed on the label that is rolling, repeatable operation equably, until forming film-coat, promptly get Film coated tablets; Or pan coating method: wrap sub-coat, enteric material and sugarcoating layer respectively and promptly get the fibrauretin coated tablet.
Embodiment 8, choose the coating material place of following weight or volume, make fibrauretin enteric coating of the present invention (in every tablet recipe amount): 28mgII acrylic resin, 16.8mg Oleum Ricini, 0.56ml 85% ethanol, 5.6mg diethyl phthalate, 805.6mg Polysorbate, 16.8mg Pulvis Talci, the coating method of enteric coating has the pan coating method: promptly wrap sub-coat, enteric material and sugarcoating layer respectively promptly outside qualified label;
Embodiment 9, choose the sugar-coat coating material prescription of following weight or volume, make fibrauretin coated tablet of the present invention (in every tablet recipe amount): 90mg Pulvis Talci, 100mg sucrose, an amount of gelatin, an amount of ferrum oxide, an amount of Cera Chinensis; The art for coating of coated tablet: get qualified label, wrap 3～5 layers of sealing coat (40～50 ℃ of dryings) earlier, wrap sub-coat and sugarcoating layer again with rubber cement, must be dry layer by layer, polishing promptly gets coated tablet after quality inspection is qualified.
Claims (10)
1, a kind of is the fibrauretin coated tablet of active component with the principal agent fibrauretin, and it is made up of label and coating membrane, it is characterized in that containing fibrauretin 10mg～1000mg by active component in the every label.
2, fibrauretin coated tablet according to claim 1 is characterized in that containing 50mg or 100mg or 200mg by every of active component in the label of coated tablet.
3, fibrauretin coated tablet according to claim 1 and 2 is characterized in that described label is mixed and made into by at least a adjuvant in principal agent fibrauretin and filler, wetting agent, binding agent, disintegrating agent, the lubricant; The weight proportion scope of principal agent and adjuvant is 1: 0.05----1: 500.
4, fibrauretin coated tablet according to claim 3, the filler that it is characterized in that one of adjuvant can adopt a kind of in starch, pregelatinized Starch, dextrin, Icing Sugar, lactose, microcrystalline Cellulose, calcium sulfate, calcium carbonate, the light magnesium oxide at least, and common dose be account for sheet heavy 30%～70%; The wetting agent of one of adjuvant can adopt distilled water or ethanol (30%～70%); The binding agent of one of adjuvant can adopt at least hypromellose (1%～10%), polyvidone (1%～20%), corn starch liquid (3%～30%), dextrin (3%～30%), syrup (10%～70%) (g/g), a kind of in gelatine size (10%～20%), mucialga of arabic gummy (10%～25%), cellulose and derivant (1%～10%) thereof, the Polyethylene Glycol; The disintegrating agent of one of adjuvant can adopt a kind of in crosslinked carboxycellulose sodium, polyvinylpolypyrrolidone, dry starch, carboxymethyl starch sodium, hydroxypropyl starch, low-substituted hydroxypropyl cellulose, sodium laurylsulfate, stearyl alcohol sodium sulfonate, bromination hexadecane trimethylamine, aluminium-magnesium silicate, kaolin, extra large bath acid, the leguminous plant glue at least, and common dose be account for sheet heavy 0.5%～20%; The lubricant of one of adjuvant can adopt a kind of in stearic acid, calcium stearate, magnesium stearate, zinc stearate, Stepanol MG, sodium lauryl sulphate, micropowder silica gel, Pulvis Talci, liquid paraffin, the sodium benzoate at least, and common dose be account for sheet heavy 0.1%～5%.
5, fibrauretin coated tablet according to claim 1 and 2, it is characterized in that slow releasing tablet and controlled release tablet that described label is made by principal agent fibrauretin and slow-release material, controlled-release material, wherein slow-release material, controlled-release material are made up of following, and it can adopt a kind of as thickening agent in gelatin, PVP, CMC, PVA, the dextran at least; At least can adopt MC, CMC-Na, HPMC, PVC, alginate, take off a kind of in ethyl acyl chitin, ethyl cellulose, polymethacrylates, the polyethylene as framework material; At least can adopt a kind of in Animal fat, Cera Flava, Brazil wax, hydrogenated vegetable oil, cellulose acetate phthalate ester, acrylic resin, hypromellose phthalate ester, the Hydroxypropyl Methyl Cellulose Phthalate as blocker.
6, according to claim 3 or 4 or 5 described fibrauretin coated tablet, it is characterized in that the outer coating membrane that coats of described label is the enteric coating film, it selects at least a among CAP, Lac, acrylic resin, the HPMCP for use.
7, according to claim 3 or 4 or 5 described fibrauretin coated tablet, it is characterized in that the outer coating membrane that coats of described label is the sugar-coat film, it comprises selects at least a as isolated material in 10%～15% rubber cement, 30%～35% mucialga of arabic gummy, 15%～20% Lac alcoholic solution, 10% zein alcoholic solution, the 10% cellulose acetate phthalate ester ethanol acetone soln for use; Select for use 65% (g/g) or 84% (g/ml) syrup as the sugarcoating layer material simultaneously; Selecting for use Pulvis Talci, Pulvis Talci to add 10%～20% calcium carbonate, Pulvis Talci adds 10%～20% magnesium carbonate, Pulvis Talci and adds at least a as the sub-coat material in 10%～20% starch; Select at least a in river wax, Cera Flava, the Brazil wax for use as the polishing agent.
8, according to claim 3 or 4 or 5 described fibrauretin coated tablet, it is characterized in that the outer coating membrane that coats of described label is the film-coat film, this film-coat film comprises selects at least a as the film-coat material in hypromellose, hydroxypropyl cellulose, ethyl cellulose, Polyethylene Glycol, polyvidone, esters of acrylic acid, zein, hydroxyethyl-cellulose, sodium carboxymethyl cellulose, the methylcellulose for use; Select at least a for plasticizer in propylene glycol, glycerol, FEG, triacetin, silicone oil, span, acetylation monoglyceride, the phthalic acid ester simultaneously for use; Select at least a in water, ethanol, isopropyl alcohol, the acetone for use as solvent.
9, a kind of preparation is as the method for claim 1-4 or the described fibrauretin coated tablet of 6---8, it is characterized in that it is to produce label by wet granule compression tablet method or compressing dry granulation or direct compression process again after earlier principal agent and adjuvant being mixed, wherein (1) wet granule compression tablet method is, get fibrauretin and pharmaceutic adjuvant by weight ratio, add an amount of wetting agent or binding agent, stir and make soft material, granulate, dry back granulate adds the lubricant mixing, and tabletting makes; (2) compressing dry granulation is, gets fibrauretin and pharmaceutic adjuvant mixing by weight, and control moisture (about 4%) is pressed into bulk or big lamellar, is broken into granule, tabletting; (3) direct compression process is, gets after fibrauretin and the suitable auxiliary materials and mixing without granulation direct compression by weight; Last coating is made coated tablet, and described art for coating has the art for coating of (1), coated tablet: get qualified label, wrap 3～5 layers of sealing coat (40～50 ℃ of dryings) earlier with rubber cement, wrap sub-coat and sugarcoating layer again, must be dry layer by layer, polishing promptly gets coated tablet after quality inspection is qualified.(2) art for coating of Film coated tablets has, the pan coating method: get qualified label, coating material is sprayed on the label that is rolling equably, repeatable operation until forming film-coat, promptly gets Film coated tablets; Or air suspension coating: qualified label is placed the coating chamber, and thermal air current directly feeds the coating chamber, plain sheet is blown afloat make into suspended state, and coating solution is sprayed on the label continuously, promptly gets Film coated tablets after the drying; (3) art for coating of enteric coatel tablets has, the pan coating method: wrap sub-coat, enteric material and sugarcoating layer respectively promptly; Or it is similar with the coating of Film coated tablets.
10, a kind of preparation is characterized in that producing earlier fibrauretine sustained-release label, controlled release label as the method for the described fibrauretin coated tablet of claim 5---8, and its method is (1) with gelatin or vinyl acetate or Lac is that binding agent is made tabletting behind the granule; (2) microcapsule compressed tablet method: for the capsule material carries out microencapsulation, make microcapsule with the blocker, repress is made sheet; (3) medicine is made piller, and then tablet forming; With the coated coated tablet of making of the label of making, described art for coating has the art for coating of (1), coated tablet: get qualified label, wrap 3～5 layers of sealing coat (40～50 ℃ of dryings) earlier with rubber cement, wrap sub-coat and sugarcoating layer again, must be dry layer by layer, polishing promptly gets coated tablet after quality inspection is qualified.(2) art for coating of Film coated tablets has, the pan coating method: get qualified label, coating material is sprayed on the label that is rolling equably, repeatable operation until forming film-coat, promptly gets Film coated tablets; Or air suspension coating: qualified label is placed the coating chamber, and thermal air current directly feeds the coating chamber, plain sheet is blown afloat make into suspended state, and coating solution is sprayed on the label continuously, promptly gets Film coated tablets after the drying; (3) art for coating of enteric coatel tablets has, the pan coating method: wrap sub-coat, enteric material and sugarcoating layer respectively promptly; Or it is similar with the coating of Film coated tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100017668A CN1557311A (en) | 2004-01-30 | 2004-01-30 | Fibrauretine capsule tablet and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100017668A CN1557311A (en) | 2004-01-30 | 2004-01-30 | Fibrauretine capsule tablet and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1557311A true CN1557311A (en) | 2004-12-29 |
Family
ID=34350643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100017668A Pending CN1557311A (en) | 2004-01-30 | 2004-01-30 | Fibrauretine capsule tablet and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1557311A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102107127A (en) * | 2011-01-11 | 2011-06-29 | 西安蓝晓科技有限公司 | Technology for granulating powder |
| CN102552199A (en) * | 2012-02-03 | 2012-07-11 | 云南昊邦制药有限公司 | Bulleyaconitine a controlled release tablet |
| CN102626397A (en) * | 2012-04-25 | 2012-08-08 | 云南植物药业有限公司 | Hydrophilic gel type palmatine sustained-release tablet and preparation method thereof |
| CN103283919A (en) * | 2012-03-01 | 2013-09-11 | 颜甄仪 | Preparation method of candies |
| CN106938047A (en) * | 2017-04-14 | 2017-07-11 | 青岛市第三人民医院 | A kind of pepsin coating tablet |
| CN106975076A (en) * | 2017-04-14 | 2017-07-25 | 青岛市第三人民医院 | A kind of pepsin coating tablet containing Chinese medical extract |
-
2004
- 2004-01-30 CN CNA2004100017668A patent/CN1557311A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102107127A (en) * | 2011-01-11 | 2011-06-29 | 西安蓝晓科技有限公司 | Technology for granulating powder |
| CN102107127B (en) * | 2011-01-11 | 2015-04-22 | 西安蓝晓科技新材料股份有限公司 | Technology for granulating powder |
| CN102552199A (en) * | 2012-02-03 | 2012-07-11 | 云南昊邦制药有限公司 | Bulleyaconitine a controlled release tablet |
| CN103283919A (en) * | 2012-03-01 | 2013-09-11 | 颜甄仪 | Preparation method of candies |
| CN102626397A (en) * | 2012-04-25 | 2012-08-08 | 云南植物药业有限公司 | Hydrophilic gel type palmatine sustained-release tablet and preparation method thereof |
| CN106938047A (en) * | 2017-04-14 | 2017-07-11 | 青岛市第三人民医院 | A kind of pepsin coating tablet |
| CN106975076A (en) * | 2017-04-14 | 2017-07-25 | 青岛市第三人民医院 | A kind of pepsin coating tablet containing Chinese medical extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6703044B1 (en) | Venlafaxine formulations | |
| RU2141822C1 (en) | New controlled-release granules and pharmaceutical preparations containing such granules | |
| AU2002317360B2 (en) | Controlled drug delivery systems providing variable release rates | |
| US8277843B2 (en) | Programmable buoyant delivery technology | |
| US4505890A (en) | Controlled release formulation and method | |
| EP1578406B1 (en) | Modified release pharmaceutical composition | |
| US20190125711A1 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| DK176018B1 (en) | Formulation with pyridoxine, HCl and doxylamine succinate, its use and process for its preparation | |
| WO2009047802A2 (en) | Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof | |
| IE59797B1 (en) | Diffusion coated multiple-units dosage form | |
| LT4844B (en) | Enteric coated pharmaceutical tablet and method of manufacturing | |
| CN102369000A (en) | Pharmaceutical composition comprising one or more fumaric acid esters | |
| CN104288774B (en) | A kind of enteric coating, dimethyl fumarate enteric coated preparations and preparation method thereof | |
| NO20121414A1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| WO2002039982A1 (en) | Oral formulations for localized colonic release and the method of preparation thereof | |
| EP2599477A1 (en) | 4-Phenylbutyric acid sustained release formulation | |
| AU2007255392B2 (en) | Process for making multiparticulates using a roller compactor | |
| CN1557311A (en) | Fibrauretine capsule tablet and its preparation method | |
| JP2000128779A (en) | Controlled release medicine type preparation | |
| CN102188388B (en) | Diclofenac sodium sustained-release pellet preparation and preparation method thereof | |
| CN110893179A (en) | Aspirin sustained-release capsule and preparation method thereof | |
| US20160045442A1 (en) | Stable pharmaceutical compositions of mesalamine | |
| JP4224866B2 (en) | Base with controlled dissolution time | |
| CA2503380A1 (en) | Pharmaceutical compositions containing venlafaxine | |
| CN103768034A (en) | Sustained or controlled release solid composition comprising bupropion hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |